Serum Institute of India said on Friday it would receive $150 million in funding from the Bill & Melinda Gates Foundation and the GAVI vaccines alliance to make 100 million COVID-19 vaccine doses for India and other emerging economies as early as 2021.
The candidate vaccines, including those from AstraZeneca and Novavax, will be priced at $3 (Rs 225) per dose and will be made available in 92 countries in GAVI's COVAX Advance Market Commitment (AMC), the company said in a statement.
The Gates Foundation will provide the funds to GAVI, which will be used to support Serum Institute.
GAVI, backed by the Gates Foundation, is a public-private global health partnership with the goal of increasing access to immunization in poor countries.
It co-leads COVAX - a scheme designed to guarantee fast and equitable access globally to COVID-19 vaccines - along with the World Health Organization and the Coalition for Epidemic Preparedness Innovations (CEPI).
COVAX aims to deliver 2 billion doses of approved and effective COVID-19 vaccines by the end of 2021.
India reported a record jump in daily coronavirus infections on Friday and became the third country in the world to surpass 2 million cases. It lags only the United States and Brazil in the number of infections.
Study Shows How Long Covid Is Debilitating Children's Health Serum Institute Says Working To Develop Monkeypox Vaccine Serum Institute's New "High Efficacy" Malaria Vaccine Rolls Out In Africa "Biggest Breach": Thousands Of Pagers Explode In Lebanon, Target Hezbollah Video: Leopard Spotted Crossing Road In Bengaluru's Electronic City AAP Asks Its Rajya Sabha MP Swati Maliwal To Quit Over Atishi Remarks "No U-Turns By Modi Government, Only Responsiveness": Piyush Goyal Exclusive How PM's Birthplace Vadnagar Shaped His Early Days, Documentary Reveals Italy PM Giorgia Meloni Wishes PM Modi On His 74th Birthday Track Latest News Live on NDTV.com and get news updates from India and around the world.